SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Contineum Therapeutics, Inc.

(Name of Issuer)

Class A Common Stock, $0.001 par value per share

(Title of Class of Securities)

(CUSIP Number)

09/22/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☑ Rule 13d-1(c)
- ☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Trails Edge Capital Partners, LP	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially	5	Sole Voting Power 1,679,443.00

Owned by Each Reporting Person With:	6	Shared Voting Power 0.00
	7	Sole Dispositive Power 1,679,443.00
	8	Shared Dispositive Power 0.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 1,679,443.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 5.1 %
12		Type of Reporting Person (See Instructions) IA, PN

Comment for Type of Reporting Person: See Item 4 for additional information.

SCHEDULE 13G

CUSIP No.

1		Names of Reporting Persons Trails Edge Biotechnology Master Fund, LP
2		Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3		Sec Use Only
4		Citizenship or Place of Organization CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 1,679,443.00
	6	Shared Voting Power 0.00
	7	Sole Dispositive Power 1,679,443.00
	8	Shared Dispositive Power 0.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 1,679,443.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9)

5.1 %

Type of Reporting Person (See Instructions)

12 PN

Comment for Type of Reporting Person: See Item 4 for additional information.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Ortav Yehudai	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 1,679,443.00
	6	Shared Voting Power 0.00
	7	Sole Dispositive Power 1,679,443.00
	8	Shared Dispositive Power 0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,679,443.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 5.1 %	
12	Type of Reporting Person (See Instructions) IN	

Comment for Type of Reporting Person: See Item 4 for additional information.

SCHEDULE 13G

Item 1.

(a) Name of issuer:

Contineum Therapeutics, Inc.

(b) Address of issuer's principal executive offices:

3565 General Atomics Court, Suite 200, San Diego, CA, 92121

Item 2.

(a) Name of person filing:

This report on Schedule 13G is being filed by Trails Edge Capital Partners, LP, a Delaware limited partnership ("Trails Edge Capital"), Trails Edge Biotechnology Master Fund, LP, a Cayman Islands limited partnership ("Trails Edge Biotechnology"), and Ortav Yehudai ("Mr. Yehudai"). Trails Edge Capital is the investment manager to Trails Edge Biotechnology, and Mr. Yehudai is the Chief Investment Officer of Trails Edge Capital. Each of Trails Edge Capital, Trails Edge Biotechnology and Mr. Yehudai are referred to individually as a "Filer" and collectively as the "Filers".

(b) Address or principal business office or, if none, residence:

The address for each Filer is 3445 Peachtree Road NE, Suite 900, Atlanta, GA 30326.

(c) Citizenship:

See Item 4 of the cover page of each Filer.

(d) Title of class of securities:

Class A Common Stock, $0.001 par value per share

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) Amount beneficially owned:

As of September 22, 2026 (the "Event Date"), each Filer may be deemed to beneficially own an aggregate of 1,679,443 shares of Class A Common Stock, $0.001 par value per share (the "Shares"), of Contineum Therapeutics, Inc. (the "Issuer"). The 1,679,443 Shares reported as beneficially owned on this Schedule 13G by each Filer consist of 1,679,443 Shares held directly by Trails Edge Biotechnology. As a result, Trails Edge Biotechnology beneficially owns 5.1% of the outstanding Shares of the Issuer as of the Event Date. Trails Edge Capital, as the investment manager to Trails Edge Biotechnology, may be deemed to beneficially own these securities. Mr. Yehudai, as the Chief Investment Officer of Trails Edge Capital, exercises voting and investment discretion with respect to these securities and as such may be deemed to beneficially own 5.1% of the outstanding Shares of the Issuer as of the Event Date. Ownership percentages are based on 32,958,632 Shares issued and outstanding as of July 24, 2026, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on July 30, 2026.

(b) Percent of class:

5.1 %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

1,679,443

(ii) Shared power to vote or to direct the vote:

0.00

(iii) Sole power to dispose or to direct the disposition of:

1,679,443

(iv) Shared power to dispose or to direct the disposition of:

0.00

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Trails Edge Capital Partners, LP

Signature: /s/ Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai

Name/Title: Ortav Yehudai / Chief Investment Officer of Trails Edge Capital Partners, LLC

Date: 10/22/2026

Trails Edge Biotechnology Master Fund, LP

Signature: /s/ Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai

Name/Title: Ortav Yehudai / Chief Investment Officer of Trails Edge GP, LLC

Date: 10/22/2026

Ortav Yehudai

Signature: /s/ Ortav Yehudai

Name/Title: Ortav Yehudai / Individual

Date: 10/22/2026

Exhibit Information

Exhibit 1- Joint Filing Agreement

Exhibit 1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of them of a statement on Schedule 13G (including amendments thereto) with respect to the Class A Common Stock, $0.001 par value per share, of Contineum Therapeutics, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as Exhibit 1 to such Schedule 13G. In evidence thereof, the undersigned hereby execute this agreement this 22nd day of October, 2026.

Trails Edge Capital Partners, LP

By: Trails Edge Capital Partners, LLC, its general partner

By: *\/s\/ Ortav Yehudai*
Name: Ortav Yehudai
Title: Chief Investment Officer

Trails Edge Biotechnology Master Fund, LP

By: Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP

By: Trails Edge GP, LLC, its general partner

By: *\/s\/ Ortav Yehudai*
Name: Ortav Yehudai
Title: Chief Investment Officer

\/s\/ Ortav Yehudai
Ortav Yehudai